MetaCap

Aardvark Therapeutics (AARD) vs IGC Pharma (IGC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

IGC Pharma (IGC) has outperformed Aardvark Therapeutics (AARD) over the past year, losing 47.5% versus a loss of 90.2%. Aardvark Therapeutics is the larger company by market cap ($20.2 million vs $19.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AARD-90.15%IGC-47.50%
+77%-11%-98%
Nov 21, 20251 yearNov 20, 2026
AARD-93.06%IGC-45.81%
+45%-27%-100%
Feb 10, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AARD versus IGC key metrics
MetricAARDIGC
Share price$0.9226$0.168
Market cap$20.20M$19.60M
1-day change-7.74%-8.70%
YTD return-92.97%-40.00%
1-year return-90.15%-47.50%
5-year return—-87.65%
EPS (TTM)$-3.33$-0.07
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$1.27M
Revenue growth (YoY)—-5.50%
Net income (latest FY)$-57.59M$-7.12M
Gross margin—48.70%
Operating margin—-585.84%
Net margin—-560.35%
52-week high$16.60$0.36
52-week low$0.90$0.08
Distance from 52-week high-94.44%-53.33%
Analyst consensusbuynone
Avg. price target upside+1104.21%+3471.43%
Average volume643.53K615.25K
Shares outstanding21.89M116.69M
Employees2870
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IGC has outperformed AARD by 42.7 percentage points over the past year.

About Aardvark Therapeutics

AARD stock →

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.

Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees

About IGC Pharma

IGC stock →

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's.

Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees

AARD vs IGC FAQ

Which is bigger, Aardvark Therapeutics or IGC Pharma?

Aardvark Therapeutics (AARD) is larger, with a market capitalization of $20.20M compared with $19.60M for IGC Pharma (IGC).

Which stock has performed better over the past year, AARD or IGC?

IGC returned -47.50% over the past 12 months, compared with -90.15% for AARD (price return, excluding dividends). Past performance does not predict future results.

Are Aardvark Therapeutics and IGC Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons